|
Report Date : |
14.11.2014 |
IDENTIFICATION DETAILS
|
Name : |
MIDAS PHARMA GMBH |
|
|
|
|
Registered Office : |
Rheinstr. 49, D 55218 Ingelheim |
|
|
|
|
Country : |
Germany |
|
|
|
|
Date of Incorporation : |
15.03.1988 |
|
|
|
|
Com. Reg. No.: |
HRB 22154 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Wholesale of Pharmaceutical Goods |
|
|
|
|
No. of Employees : |
28 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 1, 2014
|
Country Name |
Previous Rating (31.03.2014) |
Current Rating (01.06.2014) |
|
Germany |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
GERMANY - ECONOMIC OVERVIEW
The German economy - the
fifth largest economy in the world in PPP terms and Europe's largest - is a
leading exporter of machinery, vehicles, chemicals, and household equipment and
benefits from a highly skilled labor force. Like its Western European
neighbors, Germany faces significant demographic challenges to sustained
long-term growth. Low fertility rates and declining net immigration are
increasing pressure on the country's social welfare system and necessitate
structural reforms. Reforms launched by the government of Chancellor Gerhard
SCHROEDER (1998-2005), deemed necessary to address chronically high
unemployment and low average growth, has contributed to strong growth and falling
unemployment. These advances, as well as a government subsidized, reduced
working hour scheme, help explain the relatively modest increase in
unemployment during the 2008-09 recession - the deepest since World War II -
and its decrease to 5.3% in 2013. The new German government introduced a
minimum wage of $11 per hour to take effect in 2015. Stimulus and stabilization
efforts initiated in 2008 and 2009 and tax cuts introduced in Chancellor Angela
MERKEL's second term increased Germany's total budget deficit - including
federal, state, and municipal - to 4.1% in 2010, but slower spending and higher
tax revenues reduced the deficit to 0.8% in 2011 and in 2012 Germany reached a
budget surplus of 0.1%. A constitutional amendment approved in 2009 limits the
federal government to structural deficits of no more than 0.35% of GDP per
annum as of 2016 though the target was already reached in 2012. Following the
March 2011 Fukushima nuclear disaster, Chancellor Angela MERKEL announced in
May 2011 that eight of the country's 17 nuclear reactors would be shut down
immediately and the remaining plants would close by 2022. Germany hopes to
replace nuclear power with renewable energy. Before the shutdown of the eight
reactors, Germany relied on nuclear power for 23% of its electricity generating
capacity and 46% of its base-load electricity production.
|
Source
: CIA |
MIDAS Pharma GmbH
Company Status: active
Rheinstr. 49
D 55218 Ingelheim
Telephone:06132/9900
Telefax: 06132/99040
Homepage: www.midas-pharma.com
E-mail: info@midas-pharma.com
DE148264856
Business relations are permissible.
LEGAL FORM Private
limited company
Date of foundation: 1988
Shareholders'
agreement:
25.02.1988
Registered on: 15.03.1988
Commercial Register: Local court 55116 Mainz
under: HRB
22154
EUR 54,000.00
Shareholder:
K. H. Schleicher
Vermögensverwaltungsgesellschaft
mbH
Rheinstr. 49
D 55218 Ingelheim
Legal form: Private
limited company
Share capital: EUR 25,000.00
Share: EUR 54,000.00
Registered on: 25.05.2001
Reg. data: 55116 Mainz,
HRB 23169
Manager:
Dirk Weidenbach
Oberer Zwerchweg 12
D 55218 Ingelheim
authorized to jointly
represent the company
born: 25.09.1963
Manager:
Dr. Marcus Stumpf
D 55268 Nieder-Olm
authorized to jointly represent the
company
born: 12.05.1969
Manager:
Dr. Oliver Weyand
D 65033 Wiesbaden
authorized to jointly
represent the company
born: 04.10.1971
Proxy:
Michael Suess
D 55437 Ockenheim
authorized to jointly
represent the company
born: 01.06.1961
Proxy:
Ulrich Baußmann
Virchowstr. 42
D 75015 Bretten
authorized to jointly
represent the company
born: 22.01.1967
Profession: graduate
engineer
Marital status: single
Proxy:
Silvia Böhler
D 55218 Ingelheim
authorized to jointly
represent the company
born: 04.01.1965
Proxy:
Ellen Engel
D 63589 Linsengericht
authorized to jointly
represent the company
born: 06.03.1961
née: Breckheimer
Marital status: unknown
Proxy:
Dr. Peter Markus
D 51067 Köln
authorized to jointly
represent the company
born: 10.04.1964
Proxy:
Stefan Schröder
D 55218 Ingelheim
authorized to jointly
represent the company
born: 20.04.1965
Proxy:
Stefan Kaulen
D 55270 Essenheim
authorized to jointly
represent the company
born: 22.01.1961
Proxy:
Hiltrud Rubrecht
D 55599 Siefersheim
authorized to jointly
represent the company
born: 12.02.1968
Main industrial sector
46461
Wholesale of pharmaceutical goods
46750
Wholesale of chemical products
Payment experience: within agreed terms
Negative information:We have no negative
information at hand.
Type of
ownership: Tenant
Address Rheinstr.
49
D 55218 Ingelheim
Real Estate of: Dr.
Oliver Weyand
Type of ownership: unknown
Address D
65033 Wiesbaden
Land register documents were not available.
Principal banks
MAINZER VOLKSBANK ZW GAU-ALGESHEIM, 55433
GAU-ALGESHEIM
Sort. code: 55190000
BIC: MVBMDE55XXX
SPARKASSE RHEIN-NAHE, 55435 GAU-ALGESHEIM
Sort. code: 56050180
BIC: MALADE51KRE
DEUTSCHE BANK, 55020 MAINZ A RHEIN
Sort. code: 55070040
BIC: DEUTDE5MXXX
Financial year: 01.01. - 31.12.
Turnover: 2012 EUR 66,000,000.00
2013 EUR 66,000,000.00
further business figures:
Share
capital:
EUR 54,000.00
Equipment: EUR 250,000.00
Ac/ts receivable: EUR 3,500,000.00
Liabilities: EUR 300,000.00
Total numbers of vehicles: 12
Employees:
28
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.61.56 |
|
|
1 |
Rs.97.10 |
|
Euro |
1 |
Rs.76.61 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
NIT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record
(10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.